Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
TSE/TYO:2395
Japanese Market
Holding JP:2395?
Track your performance easily

Shin Nippon Biomedical Laboratories, Ltd. (2395) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

2395 Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Shin
Nippon Biomedical Laboratories, Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2395 Stock 12 Month Forecast

Average Price Target

¥1,180.00
▲(1.29% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Shin Nippon Biomedical Laboratories, Ltd. in the last 3 months. The average price target is ¥1,180.00 with a high forecast of ¥1,180.00 and a low forecast of ¥1,180.00. The average price target represents a 1.29% change from the last price of ¥1,165.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1152":"¥1,152","1475":"¥1,475","1798":"¥1,798","1313.5":"¥1,313.5","1636.5":"¥1,636.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥1.18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥1.18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.18K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1152,1313.5,1475,1636.5,1798],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Mar<br/>2024","9":"Jun<br/>2024","12":"Sep<br/>2024","25":"Sep<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1153,1155.076923076923,1157.1538461538462,1159.2307692307693,1161.3076923076924,1163.3846153846155,1165.4615384615386,1167.5384615384614,1169.6153846153845,1171.6923076923076,1173.7692307692307,1175.8461538461538,1177.923076923077,{"y":1180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1153,1155.076923076923,1157.1538461538462,1159.2307692307693,1161.3076923076924,1163.3846153846155,1165.4615384615386,1167.5384615384614,1169.6153846153845,1171.6923076923076,1173.7692307692307,1175.8461538461538,1177.923076923077,{"y":1180,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1153,1155.076923076923,1157.1538461538462,1159.2307692307693,1161.3076923076924,1163.3846153846155,1165.4615384615386,1167.5384615384614,1169.6153846153845,1171.6923076923076,1173.7692307692307,1175.8461538461538,1177.923076923077,{"y":1180,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1797.29,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1661.98,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1597.27,"date":1701043200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1610.01,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1746.3,"date":1704326400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1669.82,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1589.42,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1503,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1542,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1386,"date":1717372800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1395,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1222,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1153,"date":1725235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥1,180Average Price Target¥1,180Lowest Price Target¥1,180
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article

2395 Analyst Recommendation Trends

Rating
Aug 24
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
total
1
In the current month, 2395 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 2395 average Analyst price target in the past 3 months is ¥1,180.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

2395 Financial Forecast

2395 Earnings Forecast

Next quarter’s earnings estimate for 2395 is ¥26.89 with a range of ¥26.89 to ¥26.89. The previous quarter’s EPS was ¥2.93. 2395 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.08% of the time in the same period. In the last calendar year 2395 has Underperformed its overall industry.
Next quarter’s earnings estimate for 2395 is ¥26.89 with a range of ¥26.89 to ¥26.89. The previous quarter’s EPS was ¥2.93. 2395 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.08% of the time in the same period. In the last calendar year 2395 has Underperformed its overall industry.

2395 Sales Forecast

Next quarter’s sales forecast for 2395 is ¥6.26B with a range of ¥5.41B to ¥7.10B. The previous quarter’s sales results were ¥5.55B. 2395 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 52.88% of the time in the same period. In the last calendar year 2395 has Underperformed its overall industry.
Next quarter’s sales forecast for 2395 is ¥6.26B with a range of ¥5.41B to ¥7.10B. The previous quarter’s sales results were ¥5.55B. 2395 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 52.88% of the time in the same period. In the last calendar year 2395 has Underperformed its overall industry.

2395 Stock Forecast FAQ

What is JP:2395’s average 12-month price target, according to analysts?
Based on analyst ratings, Shin Nippon Biomedical Laboratories, Ltd.’s 12-month average price target is ¥1,180.00.
    What is JP:2395’s upside potential, based on the analysts’ average price target?
    Shin Nippon Biomedical Laboratories, Ltd. has 1.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Shin Nippon Biomedical Laboratories, Ltd. a Buy, Sell or Hold?
          Shin Nippon Biomedical Laboratories, Ltd. has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Shin Nippon Biomedical Laboratories, Ltd.’s share price target?
            The average share price target for Shin Nippon Biomedical Laboratories, Ltd. is ¥1,180.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥1,180.00 ,and the lowest forecast is ¥1,180.00. The average share price target represents 1.29% Increase from the current price of ¥1,165.
              What do analysts say about Shin Nippon Biomedical Laboratories, Ltd.?
              Shin Nippon Biomedical Laboratories, Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Shin Nippon Biomedical Laboratories, Ltd.?
                To buy shares of JP:2395, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis